Short Interest Reporting: Time to Reconsider Sarepta Therapeutics DE (NASDAQ:SRPT) After Less Short Sellers?

November 16, 2016 - By Vivian Park   ·   0 Comments

Short Interest Reporting: Time to Reconsider Sarepta Therapeutics DE (NASDAQ:SRPT) After Less Short Sellers?

The stock of Sarepta Therapeutics DE (NASDAQ:SRPT) registered a decrease of 3.49% in short interest. SRPT’s total short interest was 14.28M shares in November as published by FINRA. Its down 3.49% from 14.80M shares, reported previously. With 3.50 million shares average volume, it will take short sellers 4 days to cover their SRPT’s short positions. The short interest to Sarepta Therapeutics DE’s float is 35.2%. About 1.44 million shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 72.23% since April 14, 2016 and is uptrending. It has outperformed by 67.54% the S&P500.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $2.09 billion. The Firm is focused on the discovery and development of ribonucleic acid -targeted therapeutics for the treatment of rare, infectious and other diseases. It currently has negative earnings. The Firm operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Insitutional Activity: The institutional sentiment increased to 1.16 in Q2 2016. Its up 0.32, from 0.84 in 2016Q1. The ratio is positive, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Legal & General Public Limited Liability Corporation accumulated 0% or 7,192 shares. California State Teachers Retirement System, a California-based fund reported 89,609 shares. Art Limited Liability Corp, a New York-based fund reported 210,797 shares. Acuta Capital Limited last reported 1.19% of its portfolio in the stock. First Manhattan holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 3,000 shares. Blackrock Grp Limited has 0% invested in the company for 77,227 shares. Eagle Asset Management Inc has invested 0.05% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Carl Domino Inc has invested 0.23% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Citadel accumulated 164,743 shares or 0% of the stock. Cubist Systematic Strategies Ltd Liability Co accumulated 0% or 274 shares. Teacher Retirement Of Texas reported 6,034 shares or 0% of all its holdings. Citigroup accumulated 32,489 shares or 0% of the stock. Jane Street Ltd Liability Co has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Tiaa Cref Invest Management Limited Liability Co has 0% invested in the company for 258,882 shares. Voya Inv, a Georgia-based fund reported 18,231 shares.

Insider Transactions: Since September 14, 2016, the stock had 0 buys, and 8 selling transactions for $8.94 million net activity. Aphale Jayant sold $1.75 million worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) on Monday, September 19. 9,304 shares with value of $465,200 were sold by Howton David T on Monday, September 19. Another trade for 7,311 shares valued at $438,660 was made by Ruff Shamim on Thursday, September 22. Kaye Edward M. MD sold $2.41M worth of stock. Mahatme Sandesh sold $1.50 million worth of stock or 30,000 shares.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by William Blair given on Monday, September 19. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Neutral” rating given on Wednesday, April 20 by Janney Capital. On Tuesday, January 19 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. The firm has “Equal-Weight” rating given on Thursday, October 27 by Morgan Stanley. Roth Capital maintained it with “Buy” rating and $50 target price in Wednesday, August 26 report. As per Wednesday, August 5, the company rating was maintained by Roth Capital. Credit Suisse initiated the shares of SRPT in a report on Tuesday, October 18 with “Outperform” rating. The firm has “Neutral” rating by Wedbush given on Thursday, April 21. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Hold” rating by Jefferies on Tuesday, April 26. The stock has “Overweight” rating given by Piper Jaffray on Monday, August 24.

SRPT Company Profile

Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Another recent and important Sarepta Therapeutics Inc (NASDAQ:SRPT) news was published by Profitconfidential.com which published an article titled: “Sarepta Therapeutics Inc: $40.00 Is Price Support on SRPT stock” on October 30, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>